Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novamind Inc. NVMDF

Healthcare Biotechnology
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence... see more

Recent & Breaking News (OTCQB:NVMDF)

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

PR Newswire October 18, 2021

Novamind Granted DEA Licenses for Psilocybin Research

Accesswire October 13, 2021

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

PR Newswire October 11, 2021

Novamind to Present at LD Micro and KCSA Conferences

Accesswire October 8, 2021

Novamind Launches New Psychedelic Palliative Care Program

Accesswire October 7, 2021

Novamind to Deliver Keynote at PSYCH Investor Summit on October 7, 2021

Accesswire October 4, 2021

Novamind Opens 6th Integrative Psychiatry Clinic, Adds 3rd Clinical Research Site

Accesswire September 30, 2021

Novamind to Present at Benzinga Healthcare Conference

Newsfile September 29, 2021

Novamind Announces DTC Eligibility for its Common Shares

Accesswire September 24, 2021

Novamind to Present at Benzinga Healthcare Conference

Accesswire September 23, 2021

Novamind Announces Inclusion in NYSE Listed AdvisorShares Psychedelics ETF

Accesswire September 20, 2021

Novamind to Present at Life Sciences Investor Forum

Accesswire September 14, 2021

Novamind to Serve as Research Site for Karuna Therapeutics Late-Stage Clinical Trial

Accesswire September 13, 2021

Novamind Uplists to OTCQB Venture Market

Accesswire September 9, 2021

Novamind to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Accesswire September 8, 2021

Novamind Divests Non-Core Retreat Investment

Accesswire August 11, 2021

Novamind Strengthens Mental Health Expertise, Adds Communications Leader

Accesswire August 6, 2021

Novamind Opens 5th Clinic Location Specialized in Integrative Psychiatry for Patients with Treatment-Resistant Conditions

Accesswire July 29, 2021

Novamind Has Applied to Have its Common Shares Posted for Trading on the OTCQB in the United States

Accesswire July 21, 2021

Novamind Selected as Research Site for Bionomics' PTSD Clinical Trial

Accesswire July 8, 2021